Gemtuzumab ozogamicin により分子学的再寛解が得られた再発治療関連急性前骨髄球性白血病 Gemtuzumab ozogamicin successfully induced molecular remission in relapsed therapy-related acute promyelocytic leukemia
A 37-year-old woman was diagnosed with therapy-related acute promyelocytic leukemia (t-APL) in May 2006 after chemotherapy that included etoposide for ovarian cancer in November 2003. After treatment with all-trans retinoic acid in combination with chemotherapy, complete remission was attained. The patient was admitted on March 19, 2007 due to cerebral infarction and it was found that t-APL had recurred. Induction therapy with gemtuzumab ozogamicin (GO) was attempted. Molecular remission was attained without serious complication. GO is considered a promising agent to achieve molecular remission in patients with relapsed t-APL.
- 臨床血液 = The Japanese Journal of Clinical Hematology
臨床血液 = The Japanese Journal of Clinical Hematology 49(4), 270-272, 2008-04-30
The Japanese Society of Hematology